A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
复制标题
一项随机、双盲、安慰剂对照试验，对感染人类免疫缺陷病毒的受试者间歇性施用白细胞介素 2 和泼尼松。
DOI：
10.1086/377285
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
Lane,HClifford
中科院分区：
文献类型：
--
作者：
Tavel,JorgeA;Sereti,Irini;Walker,RobertE;Hahn,Barbara;Kovacs,JosephA;Jagannatha,Shyla;DaveyJr,RichardT;Falloon,Judith;Polis,MichaelA;Masur,Henry;Metcalf,JuliaA;Stevens,Randy;Rupert,Adam;Baseler,Michael;Lane,HClifford
Intermittent administration of interleukin (IL)–2 produces significant and sustained increases in CD4+T lymphocyte count in human immunodeficiency virus (HIV)–infected subjects but can be associated with dose-limiting toxicities. The primary objective of this study was to determine whether concomitant administration of prednisone could decrease these toxicities. HIV-seropositive adults receiving highly active antiretroviral therapy (HAART) were randomized to receive either (1) intermittent subcutaneous IL-2 and placebo, (2) intermittent subcutaneous IL-2 and prednisone, (3) intermittent prednisone, or (4) intermittent placebo. Prednisone decreased levels of proinflammatory cytokines during IL-2 cycles but, despite induction of expression of CD25, blunted increases in IL-2–associated CD4+T lymphocyte count. Whereas intermittent administration of IL-2 reduced basal proliferation of CD4+T cells, this effect was inhibited by prednisone, suggesting that prednisone potentially interferes with IL-2’s long-term effects on survival of T lymphocytes
